HUE060914T2 - Dihidro-pirrolo-piridin származékok - Google Patents
Dihidro-pirrolo-piridin származékokInfo
- Publication number
- HUE060914T2 HUE060914T2 HUE18743584A HUE18743584A HUE060914T2 HU E060914 T2 HUE060914 T2 HU E060914T2 HU E18743584 A HUE18743584 A HU E18743584A HU E18743584 A HUE18743584 A HU E18743584A HU E060914 T2 HUE060914 T2 HU E060914T2
- Authority
- HU
- Hungary
- Prior art keywords
- pyrrolo
- dihydro
- pyridine derivatives
- pyridine
- derivatives
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Diabetes (AREA)
- Pulmonology (AREA)
- Epidemiology (AREA)
- Ophthalmology & Optometry (AREA)
- Addiction (AREA)
- Hospice & Palliative Care (AREA)
- Hematology (AREA)
- Rheumatology (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Psychology (AREA)
- Emergency Medicine (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762523306P | 2017-06-22 | 2017-06-22 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HUE060914T2 true HUE060914T2 (hu) | 2023-04-28 |
Family
ID=62981279
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HUE18743584A HUE060914T2 (hu) | 2017-06-22 | 2018-06-14 | Dihidro-pirrolo-piridin származékok |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US11198692B2 (enExample) |
| EP (1) | EP3642202B1 (enExample) |
| JP (1) | JP7263266B2 (enExample) |
| KR (1) | KR20200013783A (enExample) |
| CN (1) | CN110944998B (enExample) |
| AU (1) | AU2018287787A1 (enExample) |
| BR (1) | BR112019026955A2 (enExample) |
| CA (1) | CA3066986A1 (enExample) |
| DK (1) | DK3642202T3 (enExample) |
| ES (1) | ES2937236T3 (enExample) |
| FI (1) | FI3642202T3 (enExample) |
| HU (1) | HUE060914T2 (enExample) |
| IL (1) | IL271290B2 (enExample) |
| MX (1) | MX2019015371A (enExample) |
| PL (1) | PL3642202T3 (enExample) |
| PT (1) | PT3642202T (enExample) |
| SG (1) | SG11201913014YA (enExample) |
| TW (1) | TWI680128B (enExample) |
| WO (1) | WO2018234953A1 (enExample) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114728964A (zh) * | 2019-11-22 | 2022-07-08 | 豪夫迈·罗氏有限公司 | 吡咯烷衍生物 |
| CN112174869B (zh) * | 2020-10-12 | 2023-04-25 | 蔡霈 | N-苯乙酰基-2-羟甲基吡咯烷-2-甲酰胺的制备方法及其药用用途 |
| TW202432557A (zh) * | 2022-10-28 | 2024-08-16 | 大陸商紐歐申醫藥（上海）有限公司 | 一種含氮雜環化合物、其藥學上可接受的鹽及其製備方法與應用 |
| CN120641414A (zh) * | 2022-12-16 | 2025-09-12 | 卡鲁娜治疗学有限公司 | 经取代的四氢吡咯并-吡啶酮化合物及其在治疗医学病状中的用途 |
| JP2025541363A (ja) * | 2022-12-16 | 2025-12-18 | カルナ セラピューティクス，インコーポレイテッド | 置換ジヒドロピロロ［３，４－ｄ］ピリミジン化合物及び医学的状態の治療におけるその使用 |
| KR20250121123A (ko) | 2022-12-16 | 2025-08-11 | 카루나 세러퓨틱스 인코포레이티드 | 치환된 테트라히드로피롤로-피리디논 화합물 및 의학적 병태를 치료하는 데 있어서의 이의 용도 |
| KR20250114139A (ko) * | 2022-12-16 | 2025-07-28 | 카루나 세러퓨틱스 인코포레이티드 | 치환된 테트라하이드로피롤로-피리디논 화합물 및 의학적 병태 치료에서의 이의 용도 |
| EP4634194A1 (en) * | 2022-12-16 | 2025-10-22 | Karuna Therapeutics, Inc. | Substituted dihydropyrrolo [3, 4-d] pyrimidine compounds and their use in treating medical conditions |
| WO2024260386A1 (zh) * | 2023-06-20 | 2024-12-26 | 西藏海思科制药有限公司 | 毒蕈碱m4受体激动剂及其用途 |
| WO2025055970A1 (zh) * | 2023-09-15 | 2025-03-20 | 江苏恩华药业股份有限公司 | 氮杂环丁烷衍生物、其制备方法及其医药用途 |
| WO2025083630A1 (en) | 2023-10-19 | 2025-04-24 | Suven Life Sciences Limited | Heteroaromatic compounds as muscarinic m4 receptor positive allosteric modulators (m4 pams) |
| WO2025099660A1 (en) | 2023-11-10 | 2025-05-15 | Suven Life Sciences Limited | Piperidine substituted compounds as muscarinic m4 receptor positive allosteric modulators (m4 pams) |
| WO2025103475A1 (zh) * | 2023-11-17 | 2025-05-22 | 上海翰森生物医药科技有限公司 | 杂环羰基类衍生物调节剂、其制备方法和应用 |
| WO2025122809A1 (en) * | 2023-12-07 | 2025-06-12 | Acadia Pharmaceuticals Inc. | M4 positive allosteric modulators |
| WO2025131049A1 (en) * | 2023-12-21 | 2025-06-26 | Ignis Therapeutics (Suzhou) Limited | Dihydro-pyrrolo-pyridine derivatives and uses thereof |
| WO2025134078A1 (en) | 2023-12-22 | 2025-06-26 | Suven Life Sciences Limited | Organic compounds as muscarinic m4 receptor positive allosteric modulators (m4 pams) |
Family Cites Families (56)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3123612A (en) * | 1964-03-03 | Z-acylated z | ||
| US2767191A (en) * | 1953-12-31 | 1956-10-16 | American Cyanamid Co | Dihydropyrrolo-pyridines |
| ATE239797T1 (de) | 1993-01-25 | 2003-05-15 | Takeda Chemical Industries Ltd | Antikörper gegen beta-amyloid oder derivative davon und seine verwendung |
| DE19709877A1 (de) | 1997-03-11 | 1998-09-17 | Bayer Ag | 1,5-Dihydro-pyrazolo[3,4-d]-pyrimidinon-derivate |
| US8173127B2 (en) | 1997-04-09 | 2012-05-08 | Intellect Neurosciences, Inc. | Specific antibodies to amyloid beta peptide, pharmaceutical compositions and methods of use thereof |
| JP3816111B2 (ja) | 1997-04-09 | 2006-08-30 | インテレクト・ニューロサイエンシズ・インコーポレーテッド | β−アミロイド末端に特異的な組換え抗体、それをコードするＤＮＡ及びその使用法 |
| GB9722520D0 (en) | 1997-10-24 | 1997-12-24 | Pfizer Ltd | Compounds |
| TWI239847B (en) | 1997-12-02 | 2005-09-21 | Elan Pharm Inc | N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease |
| US6905686B1 (en) | 1997-12-02 | 2005-06-14 | Neuralab Limited | Active immunization for treatment of alzheimer's disease |
| JP2000109481A (ja) | 1999-10-13 | 2000-04-18 | Yamanouchi Pharmaceut Co Ltd | キヌクリジン誘導体含有医薬 |
| SI1481992T1 (sl) | 2000-02-24 | 2017-01-31 | Washington University St. Louis | Humanizirana protitelesa, ki vežejo amiloidni peptid beta |
| DE10045112A1 (de) | 2000-09-11 | 2002-03-21 | Merck Patent Gmbh | Verwendung von Indolderivaten zur Behandlung von Erkrankungen des zentralen Nervensystems |
| JP4708675B2 (ja) | 2000-11-03 | 2011-06-22 | プロテオテック・インコーポレーテッド | ウンカリア・トメントーサおよび関連植物からアミロイド阻害化合物を単離する方法ならびに単離した化合物の使用 |
| WO2003016466A2 (en) | 2001-08-17 | 2003-02-27 | Eli Lilly And Company | ANTI-Aβ ANTIBODIES |
| US20030195205A1 (en) | 2001-11-02 | 2003-10-16 | Pfizer Inc. | PDE9 inhibitors for treating cardiovascular disorders |
| DE10238724A1 (de) | 2002-08-23 | 2004-03-04 | Bayer Ag | Alkyl-substituierte Pyrazolpyrimidine |
| DE10238723A1 (de) | 2002-08-23 | 2004-03-11 | Bayer Ag | Phenyl-substituierte Pyrazolyprimidine |
| CA2501945A1 (en) | 2002-10-09 | 2004-04-22 | Rinat Neuroscience Corp. | Methods of treating alzheimer's disease using antibodies directed against amyloid beta peptide and compositions thereof |
| US20040220186A1 (en) | 2003-04-30 | 2004-11-04 | Pfizer Inc. | PDE9 inhibitors for treating type 2 diabetes,metabolic syndrome, and cardiovascular disease |
| EP1638935A1 (en) | 2003-06-19 | 2006-03-29 | Pfizer Products Inc. | Nk1 antagonist |
| CA2538220A1 (en) | 2003-09-09 | 2005-03-24 | Takeda Pharmaceutical Company Limited | Use of antibody |
| GB0327319D0 (en) | 2003-11-24 | 2003-12-24 | Pfizer Ltd | Novel pharmaceuticals |
| BRPI0507374A (pt) | 2004-02-02 | 2007-07-10 | Pfizer Prod Inc | moduladores do receptor de histamina-3 |
| US7456164B2 (en) | 2004-05-07 | 2008-11-25 | Pfizer, Inc | 3- or 4-monosubtituted phenol and thiophenol derivatives useful as H3 ligands |
| EP1595881A1 (en) | 2004-05-12 | 2005-11-16 | Pfizer Limited | Tetrahydronaphthyridine derivates useful as histamine H3 receptor ligands |
| TWI355389B (en) | 2004-07-30 | 2012-01-01 | Rinat Neuroscience Corp | Antibodies directed against amyloid-beta peptide a |
| GB0423356D0 (en) | 2004-10-21 | 2004-11-24 | Merck Sharp & Dohme | Therapeutic agents |
| CN100577666C (zh) | 2004-10-25 | 2010-01-06 | 伊莱利利公司 | 作为m4毒蕈碱性受体的变构增效剂的噻吩并吡啶类 |
| WO2006069081A2 (en) | 2004-12-22 | 2006-06-29 | Washington University In St. Louis | USE OF ANTI-Aβ ANTIBODY TO TREAT TRAUMATIC BRAIN INJURY |
| NZ556434A (en) | 2005-02-07 | 2010-05-28 | Hoffmann La Roche | Heterocyclic substituted phenyl methanones as inhibitors of the glycine transporter 1 |
| UY29504A1 (es) | 2005-04-29 | 2006-10-31 | Rinat Neuroscience Corp | Anticuerpos dirigidos contra el péptido amiloide beta y métodos que utilizan los mismos. |
| PL1881985T3 (pl) | 2005-05-12 | 2011-05-31 | Pfizer | Bezwodne krystaliczne postacie N-[1-(2-etoksyetylo)-5-(N-etylo-N-metyloamino)-7-(4-metylopirydyn-2-yloamino)-1H-pirazolo[4,3-d]pirymidyno-3-karbonylo]metano-sulfonoamidu |
| WO2006126082A2 (en) | 2005-05-24 | 2006-11-30 | Pharmacia & Upjohn Company Llc | Pyridine [3,4-b] pyrazinones as pde-5 inhibitors |
| CA2603830A1 (en) | 2005-05-24 | 2006-11-30 | Pharmacia & Upjohn Co Llc | PYRIDINE [2,3-B] PYRAZINONES |
| WO2006126083A1 (en) | 2005-05-24 | 2006-11-30 | Pharmacia & Upjohn Company Llc | Pyridine [3 , 4-b] pyrazinone compounds as pde-5 inhibitors |
| WO2006136924A1 (en) | 2005-06-22 | 2006-12-28 | Pfizer Products Inc. | Histamine-3 receptor antagonists |
| US8158673B2 (en) | 2005-10-27 | 2012-04-17 | Pfizer Inc. | Histamine-3 receptor antagonists |
| JP2009514846A (ja) | 2005-11-04 | 2009-04-09 | ファイザー・リミテッド | テトラヒドロナフチリジン誘導体 |
| WO2007063385A2 (en) | 2005-12-01 | 2007-06-07 | Pfizer Products Inc. | Spirocyclic amine histamine-3 receptor antagonists |
| WO2007069053A1 (en) | 2005-12-14 | 2007-06-21 | Pfizer Products Inc. | Benzimidazole antagonists of the h-3 receptor |
| WO2007088450A2 (en) | 2006-02-01 | 2007-08-09 | Pfizer Products Inc. | Chromane antagonist of the h-3 receptor |
| WO2007088462A1 (en) | 2006-02-01 | 2007-08-09 | Pfizer Products Inc. | Spirochromane antagonists of the h-3 receptor |
| WO2007099423A1 (en) | 2006-03-02 | 2007-09-07 | Pfizer Products Inc. | 1-pyrrolidine indane derivatives as histamine-3 receptor antagonists |
| EP2007749A2 (en) | 2006-03-13 | 2008-12-31 | Pfizer Products Inc. | Tetralines antagonists of the h-3 receptor |
| CA2649775C (en) | 2006-04-21 | 2011-05-31 | Pfizer Products Inc. | Pyridine[3,4-b]pyrazinones |
| WO2007138431A2 (en) | 2006-05-30 | 2007-12-06 | Pfizer Products Inc. | Azabicyclic ether histamine-3 antagonists |
| WO2008090429A1 (en) | 2007-01-22 | 2008-07-31 | Pfizer Products Inc. | Tosylate salt of a therapeutic compound and pharmaceutical compositions thereof |
| US20100273772A1 (en) | 2009-04-23 | 2010-10-28 | Wyeth Llc | Bisaryl Alkynylamides as Negative Allosteric Modulators of Metabotropic Glutamate Receptor 5 (MGLUR5) |
| WO2012047702A1 (en) | 2010-10-04 | 2012-04-12 | Merck Sharp & Dohme Corp. | Dihydrobenzoquinazolinone m1 receptor positive allosteric modulators |
| JP6117104B2 (ja) | 2010-11-15 | 2017-04-19 | アッヴィ・インコーポレイテッド | Ｎａｍｐｔおよびｒｏｃｋ阻害薬 |
| ES2656972T3 (es) | 2012-02-23 | 2018-03-01 | Vanderbilt University | Análogos de 5-aminotieno [2,3-c] piridazin-6-carboxamida como moduladores alostéricos positivos del receptor de acetilcolina muscarínico M4 |
| WO2014035829A1 (en) | 2012-08-31 | 2014-03-06 | Vanderbilt University | Substituted 3-aminothieno[2,3-c]pyridine-2-carboxamide analogs as positive allosteric modulators |
| WO2015027204A1 (en) | 2013-08-23 | 2015-02-26 | Vanderbilt University | Substituted thieno[2,3-b]pyridine-2-carboxamide analogs as positive allosteric modulators of the muscarinic acetylcholine receptor m4 |
| EP3036233A1 (en) | 2013-08-23 | 2016-06-29 | Vanderbilt University | Substituted thieno[2,3-c]pyridazine-6-carboxamide analogs as positive allosteric modulators of the muscarinic acetylcholine receptor m4 |
| CN109641898B (zh) | 2016-07-01 | 2022-04-08 | 辉瑞公司 | 用于治疗神经和神经退行性疾病的5,7-二氢-吡咯并-吡啶衍生物 |
| GB201616839D0 (en) | 2016-10-04 | 2016-11-16 | Takeda Pharmaceutical Company Limited | Therapeutic compounds |
-
2018
- 2018-06-14 IL IL271290A patent/IL271290B2/en unknown
- 2018-06-14 HU HUE18743584A patent/HUE060914T2/hu unknown
- 2018-06-14 PT PT187435847T patent/PT3642202T/pt unknown
- 2018-06-14 FI FIEP18743584.7T patent/FI3642202T3/fi active
- 2018-06-14 SG SG11201913014YA patent/SG11201913014YA/en unknown
- 2018-06-14 KR KR1020207001865A patent/KR20200013783A/ko not_active Withdrawn
- 2018-06-14 PL PL18743584.7T patent/PL3642202T3/pl unknown
- 2018-06-14 DK DK18743584.7T patent/DK3642202T3/da active
- 2018-06-14 JP JP2019570547A patent/JP7263266B2/ja active Active
- 2018-06-14 ES ES18743584T patent/ES2937236T3/es active Active
- 2018-06-14 CN CN201880049365.XA patent/CN110944998B/zh active Active
- 2018-06-14 BR BR112019026955-0A patent/BR112019026955A2/pt not_active Application Discontinuation
- 2018-06-14 CA CA3066986A patent/CA3066986A1/en active Pending
- 2018-06-14 MX MX2019015371A patent/MX2019015371A/es unknown
- 2018-06-14 EP EP18743584.7A patent/EP3642202B1/en active Active
- 2018-06-14 US US16/625,202 patent/US11198692B2/en active Active
- 2018-06-14 AU AU2018287787A patent/AU2018287787A1/en not_active Abandoned
- 2018-06-14 WO PCT/IB2018/054390 patent/WO2018234953A1/en not_active Ceased
- 2018-06-19 TW TW107120944A patent/TWI680128B/zh active
Also Published As
| Publication number | Publication date |
|---|---|
| PT3642202T (pt) | 2023-02-02 |
| WO2018234953A1 (en) | 2018-12-27 |
| CA3066986A1 (en) | 2018-12-27 |
| TW201920166A (zh) | 2019-06-01 |
| JP7263266B2 (ja) | 2023-04-24 |
| CN110944998A (zh) | 2020-03-31 |
| IL271290A (en) | 2020-01-30 |
| JP2020524687A (ja) | 2020-08-20 |
| TWI680128B (zh) | 2019-12-21 |
| NZ760036A (en) | 2025-05-30 |
| IL271290B2 (en) | 2023-11-01 |
| EP3642202A1 (en) | 2020-04-29 |
| EP3642202B1 (en) | 2022-11-02 |
| MX2019015371A (es) | 2020-07-20 |
| DK3642202T3 (da) | 2023-01-30 |
| ES2937236T3 (es) | 2023-03-27 |
| CN110944998B (zh) | 2022-08-16 |
| FI3642202T3 (fi) | 2023-03-01 |
| KR20200013783A (ko) | 2020-02-07 |
| US20200262833A1 (en) | 2020-08-20 |
| SG11201913014YA (en) | 2020-01-30 |
| BR112019026955A2 (pt) | 2020-06-30 |
| IL271290B1 (en) | 2023-07-01 |
| PL3642202T3 (pl) | 2023-03-13 |
| US11198692B2 (en) | 2021-12-14 |
| AU2018287787A1 (en) | 2020-01-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK3731771T3 (da) | V462033dk00 | |
| DK3642202T3 (da) | Dihydro-pyrrolo-pyridin-derivater | |
| DK3319956T3 (da) | Substituerede oxopyridinderivater | |
| CL2018000524S1 (es) | Golilla | |
| DE202018003363U8 (de) | Handgelenkssphygmomanometer | |
| EP3634404C0 (en) | PYRAZOLE-BASED MAGL INHIBITORS | |
| EP3589248A4 (en) | CRYOTHERAPIES | |
| EP3588580A4 (en) | SCHOTTKY MOS TRENCH DIODE | |
| DK3351526T3 (da) | Diisopentylterephthalat | |
| EP3697802A4 (en) | TRITERPENIC SAPONIN ANALOGUES | |
| LT3402792T (lt) | Chinolin-2-ono dariniai | |
| EP3634397A4 (en) | HETEROCYCLYL POLYMETHINE-BASED IR CHROMOPHORES | |
| LT3457851T (lt) | Sobetiromo dariniai | |
| DK3568655T3 (da) | Rekuperator | |
| DK3571580T5 (da) | Load-logical-and-shift-guarded-instruktion | |
| EP3654852A4 (en) | TOURNIQUET | |
| LT3371168T (lt) | Indolin-2-ono dariniai | |
| DK3612237T3 (da) | Genterapi | |
| EP3575467A4 (en) | NON-WOVEN FABRIC THREADED | |
| EP3611402A4 (en) | SERVO CYLINDER | |
| EP3714787A4 (en) | BIOSENSOR | |
| DK3576686T3 (da) | Brokbind | |
| DK3568506T3 (da) | Offeranode | |
| EP3689701A4 (en) | BOGIE | |
| DK3645513T3 (da) | Benzazepinderivater |